Literature DB >> 27125676

Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution.

Dijana Detel1, Suncica Buljevic2, Lara Baticic Pucar2, Natalia Kucic3, Ester Pernjak Pugel4, Jadranka Varljen2.   

Abstract

A lot of evidence for the importance of CD26/dipeptidyl peptidase IV (CD26/DPP IV) in immunoactivation has been reported; however, its involvement in colitis remains unclear. The aim of this study was to investigate the influence of CD26/DPP IV deficiency on immunophenotypic changes associated with dextran sulfate sodium (DSS)-induced colitis in wild-type (WT) and CD26-deficient mice. Development of clinical symptoms of colitis and animal health status parameters were assessed; the expression of the nuclear factor (NF)-κB p65 subunit was measured by quantitative real-time PCR, while cell characterization was determined by flow cytometry and immunohistochemical staining. DSS treatment induced loss of body weight and colon length shortening in both mouse strains. An increase of myeloperoxidase activity in CD26-deficient mice was more intensive than in WT mice, in spite of similar histopathological changes. Furthermore, a significant increase in the expression of NF-κB p65 subunit in the colon of CD26-deficient mice was determined. The percentage of splenic CD4(+) and CD8(+) cells in the acute phase of colitis was significantly decreased in WT mice, while in the same period, an increase in the percentage of splenic CD8(+) cells was present in CD26-deficient mice. Development of colitis was accompanied by a significant increase in the percentage of intrahepatic NKT cells in both mouse strains, but their percentage in spleen was increased only in CD26-deficient mice. CD26 deficiency was associated with a heightened response to DSS accompanied by increased expression of NF-κB p65 subunit and distinct changes in leukocyte trafficking. These results provide new insights into the role of CD26/DPP IV during the development of colitis.

Entities:  

Keywords:  CD26-deficient animals; CD26/dipeptidyl peptidase IV; Dextran sulfate sodium; Immune response; Inflammatory bowel disease

Mesh:

Substances:

Year:  2016        PMID: 27125676     DOI: 10.1007/s13105-016-0491-7

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  38 in total

Review 1.  NF-κB in immunobiology.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

Review 2.  CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

Authors:  M D Gorrell; V Gysbers; G W McCaughan
Journal:  Scand J Immunol       Date:  2001-09       Impact factor: 3.487

Review 3.  Dipeptidyl peptidase in autoimmune pathophysiology.

Authors:  Kei Ohnuma; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Adv Clin Chem       Date:  2011       Impact factor: 5.394

Review 4.  Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.

Authors:  Kei Ohnuma; Nozomu Takahashi; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Front Biosci       Date:  2008-01-01

5.  Opposing functions of IKKbeta during acute and chronic intestinal inflammation.

Authors:  Lars Eckmann; Tim Nebelsiek; Alexander A Fingerle; Sara M Dann; Jörg Mages; Roland Lang; Sylvie Robine; Martin F Kagnoff; Roland M Schmid; Michael Karin; Melek C Arkan; Florian R Greten
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

Review 6.  NF-kappaB in inflammatory bowel disease.

Authors:  I Atreya; R Atreya; M F Neurath
Journal:  J Intern Med       Date:  2008-06       Impact factor: 8.989

7.  The role of intrahepatic CD8+ T cell trapping and NK1.1+ cells in liver-mediated immune regulation.

Authors:  Oren Shibolet; Ruslana Alper; Lydia Zolotarov; Shivti Trop; Barbara Thalenfeld; Dean Engelhardt; Elazar Rabbani; Yaron Ilan
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

8.  Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice.

Authors:  Roger Yazbeck; Gordon S Howarth; Mark S Geier; Hans-Ulrich Demuth; Catherine A Abbott
Journal:  Front Biosci       Date:  2008-05-01

Review 9.  Nuclear factor-kappa B in intestinal protection and destruction.

Authors:  Martina E Spehlmann; Lars Eckmann
Journal:  Curr Opin Gastroenterol       Date:  2009-03       Impact factor: 3.287

10.  Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA.

Authors:  Emilie Viennois; Fengyuan Chen; Hamed Laroui; Mark T Baker; Didier Merlin
Journal:  BMC Res Notes       Date:  2013-09-08
View more
  6 in total

Review 1.  Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Authors:  Hubert Zatorski; Maciej Sałaga; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-29       Impact factor: 3.000

2.  DPP4 inhibitor reinforces cell junction proteins in mouse model of short bowel syndrome.

Authors:  Ryo Sueyoshi; Katsumi Miyahara; Nana Nakazawa-Tanaka; Naho Fujiwara; Takanori Ochi; Atsuyuki Yamataka
Journal:  Pediatr Surg Int       Date:  2019-10-01       Impact factor: 1.827

Review 3.  Role of Incretin Axis in Inflammatory Bowel Disease.

Authors:  Lihua Duan; Xiaoquan Rao; Zachary Braunstein; Amelia C Toomey; Jixin Zhong
Journal:  Front Immunol       Date:  2017-12-06       Impact factor: 7.561

Review 4.  Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.

Authors:  Jie Huang; Xinxin Liu; Yingying Wei; Xinlu Li; Shupei Gao; Lingli Dong; Xiaoquan Rao; Jixin Zhong
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

5.  Lactobacillus brevis Alleviates DSS-Induced Colitis by Reprograming Intestinal Microbiota and Influencing Serum Metabolome in Murine Model.

Authors:  Sujuan Ding; Yong Ma; Gang Liu; Wenxin Yan; Hongmei Jiang; Jun Fang
Journal:  Front Physiol       Date:  2019-09-18       Impact factor: 4.566

Review 6.  A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System.

Authors:  Mingrui Li; Benno Weigmann
Journal:  Metabolites       Date:  2022-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.